Treatment Regimen for Recurrent Pulmonary Tuberculosis

Initial Treatment Approach

The American Academy of Family Physicians and the American Thoracic Society recommend treating recurrent pulmonary tuberculosis with at least four drugs in the initial phase, including a fluoroquinolone if available, based on prior treatment history and drug susceptibility testing, with the assumption of acquired drug resistance until proven otherwise 1, 2
The Centers for Disease Control and Prevention recommends obtaining drug susceptibility testing immediately before initiating treatment, as recurrent TB is highly likely to represent acquired drug resistance from inadequate prior therapy, and culture and molecular testing for resistance to at least isoniazid, rifampin, pyrazinamide, and fluoroquinolones should be performed 1, 3

The American Thoracic Society recommends a standard four-drug regimen for the initial phase (2 months) consisting of isoniazid, rifampin, pyrazinamide, and ethambutol given daily, and for the continuation phase (4 months) consisting of isoniazid and rifampin given daily, with a total duration of 6 months for non-cavitary disease with negative cultures at 2 months 1, 2, 4, 5
The American Thoracic Society recommends extending the continuation phase to 7 months (total 9 months) if cavitary disease is present on initial chest radiograph or if sputum cultures remain positive at completion of 2 months of treatment 2, 4, 5
The World Health Organization recommends starting with at least 4-5 drugs that the patient has NOT received previously until susceptibility results return, which typically includes a fluoroquinolone, an injectable agent, and other first-line drugs not previously used 1, 6, 7

The World Health Organization defines MDR-TB as resistance to at least isoniazid AND rifampin, and recommends the 6-month BPaLM regimen for eligible patients, consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin for 6 months (26 weeks) 6, 7
The World Health Organization recommends the 9-month all-oral bedaquiline-containing regimen for patients not eligible for BPaLM, consisting of an intensive phase (4-6 months) and a continuation phase (5 months) 6, 7

The Centers for Disease Control and Prevention recommends monthly sputum cultures until two consecutive negatives are documented, and patients should demonstrate sputum conversion within 3 months; if not, evaluate for non-adherence and drug resistance 3, 4
The American Thoracic Society recommends assessing clinical and bacteriologic response at least twice monthly until asymptomatic and smear-negative 4

The American Academy of Family Physicians recommends never adding a single drug to a failing regimen, as this will create further drug resistance, and always adding at least two drugs the organism has not been exposed to 4
The American Thoracic Society recommends implementing directly observed therapy (DOT) for all recurrent cases, as treatment failure is most commonly due to non-compliance 2, 4, 5